ADMA Biologics Files 8-K on Shareholder Votes & Exhibits

TL;DR

ADMA Biologics filed an 8-K for shareholder votes and financial exhibits. Details TBD.

AI Summary

On June 4, 2024, ADMA Biologics, Inc. filed an 8-K report to disclose information regarding matters submitted to a vote of security holders and financial statements/exhibits. The filing does not contain specific details on the vote outcomes or financial figures within the provided text.

Why It Matters

This filing indicates corporate actions and financial reporting updates for ADMA Biologics, Inc., which are important for investors to track company governance and financial health.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new material risks or significant negative financial events.

Key Players & Entities

• ADMA BIOLOGICS, INC. (company) — Registrant
• June 4, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Ramsey, New Jersey (location) — Principal executive offices
• R&R ACQUISITION VI, INC (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share ADMA Nasdaq Global Market

Filing Documents

• ef20030555_8k.htm (8-K) — 38KB
• 0001140361-24-028800.txt ( ) — 170KB
• adma-20240604.xsd (EX-101.SCH) — 4KB
• adma-20240604_lab.xml (EX-101.LAB) — 21KB
• adma-20240604_pre.xml (EX-101.PRE) — 16KB
• ef20030555_8k_htm.xml (XML) — 4KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders ADMA Biologics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on June 4, 2024. At the Annual Meeting, the following matters were submitted to a vote of stockholders: 1. The election of three nominees to serve as Class II directors until the Company's 2027 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, or such director's earlier resignation, removal or death; and 2. The ratification of the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. At the close of business on April 8, 2024, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 231,771,523 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The holders of 186,655,332 shares of the Company's common stock were represented virtually or by proxy at the Annual Meeting, constituting a quorum. At the Annual Meeting, (i) the three Class II directors were elected, and (ii) the appointment of the Company's independent registered public accounting firm for the Proposal No. 1 — Election of the Class II Directors The vote with respect to the election of each of the directors was as follows: Nominee For Withheld Broker Non-Votes Steven A. Elms 110,136,193 44,858,645 31,660,494 Adam S. Grossman 150,349,105 4,645,733 31,660,494 Young T. Kwon, PhD 152,744,777 2,250,061 31,660,494 Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows: For Against Abstain 184,478,528 1,

01

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. June 4, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President, Chief Executive Officer and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR